Update shared on25 Aug 2025
Fair value Decreased 9.00%The consensus analyst price target for Iovance Biotherapeutics has been revised downward to $9.10 as slower-than-expected Amtagvi commercial adoption and logistical challenges outweigh positive early clinical response data.
Analyst Commentary
- Bearish analysts cite a slower-than-expected commercial launch for Amtagvi in second-line melanoma, driving down sentiment and price targets.
- Surveys with key opinion leaders and physicians indicate underutilization of Amtagvi due to a limited eligible patient population and significant logistical and operational complexities.
- Bullish analysts highlight impressive real-world data for Amtagvi, particularly strong clinical response rates in earlier stage patients upon commercialization.
- Clinical results from 41 patients at multiple authorized centers showed a 48.8% objective response rate, viewed as exceeding expectations in less heavily treated patients.
- Ongoing divergence in price targets reflects differing weight given to commercial adoption challenges versus clinical performance in selected cohorts.
What's in the News
- Iovance completed a $350 million at-the-market follow-on equity offering.
- Health Canada granted conditional approval for Amtagvi (lifileucel) in unresectable/metastatic melanoma, pending further confirmatory trial results.
- Company reiterated 2025 total product revenue guidance of $250–300 million, driven by Amtagvi and anticipated Proleukin growth, with improving gross margins expected through manufacturing optimization.
- Corleen Roche appointed Chief Financial Officer, succeeding Jean-Marc Bellemin who resigned.
- Added to multiple Russell Value indices and removed from several Russell Growth indices, reflecting a shift in index classification.
Valuation Changes
Summary of Valuation Changes for Iovance Biotherapeutics
- The Consensus Analyst Price Target has fallen from $10.00 to $9.10.
- The Future P/E for Iovance Biotherapeutics has fallen from 151.56x to 137.92x.
- The Net Profit Margin for Iovance Biotherapeutics remained effectively unchanged, at 4.78%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.